| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 66.7 | ¤714,944 | US |
| JNJ | Johnson & Johnson | 64.4 | ¤428,829 | US |
| ABT | Abbott Laboratories | 61.7 | ¤232,752 | US |
| MRK | Merck & Co., Inc. | 62.9 | ¤206,841 | US |
| TMO | Thermo Fisher Scientific Inc. | 52.3 | ¤181,050 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| ALGN | Align Technology, Inc. | 48.3 | ¤9,536 | US |
| MOH | Molina Healthcare, Inc. | 47.4 | ¤9,804 | US |
| BMRN | BioMarin Pharmaceutical Inc. | 76.8 | ¤10,386 | US |
| COO | Cooper Companies, Inc. | 45.3 | ¤13,257 | US |
| HOLX | Hologic, Inc. | 51.9 | ¤14,335 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 62.3 | 30 | US |
| LLY | Eli Lilly and Company | 66.7 | 25 | US |
| PFE | Pfizer Inc. | 62.9 | 23 | US |
| DGX | Quest Diagnostics Incorporated | 57.8 | 21 | US |
| ZTS | Zoetis, Inc. Class A | 59.7 | 21 | US |
| JNJ | Johnson & Johnson | 64.4 | 20 | US |
| TMO | Thermo Fisher Scientific Inc. | 52.3 | 20 | US |
| RMD | ResMed Inc. | 73.3 | 18 | US |
| UTHR | United Therapeutics Corporation | 68.0 | 17 | US |
| A | Agilent Technologies, Inc. | 54.5 | 15 | US |
| Average Market Cap | ¤98,760 |
| Median Market Cap | ¤34,939 |
| Avg. 3 Mo. Dollar Vol. | ¤526,726,536 |
| Avg. 3 Mo. Trading Vol. | 4,000,979 |
| Last Rebalance Date | 03/24/2025 |
| Companies Replaced | 20 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 25.5 |
| Forward P/E Ratio (12 Mo.) | 18.1 |
| Price/Book Ratio | 4.1 |
| Avg. Revenue Chg. - 3 Yr | 9.7% |
| Avg. Op. Income Chg. - 3 Yr. | 23.4% |
| Avg. EPS Growth - 3 Yr. | 9.6% |
| Avg. EPS Growth - 1 Yr. | 9.3% |
| Avg. Operating Margin | 23.6% |
| Avg. LT Debt to Total Capital | 34.9% |
| Avg. Return on Equity | 19.2% |
| Dividend Yield | 0% |
| US Health Care Index | 60.42 |
| United States Of America | 93.33% |
| Switzerland | 3.33% |
| Ireland | 3.33% |
